Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

This study is testing the safety and early effectiveness of MT-601, a new type of T-cell therapy (an engineered immune cell treatment), in patients with lymphoma (a blood cancer) that has come back or has not responded to prior treatments. **You may be eligible if...** - You are 18 or older - You have relapsed or refractory lymphoma (lymphoma that came back or did not respond to treatment) - You are considered an appropriate candidate for experimental therapy by your treating doctor - You have signed informed consent and meet all protocol-specific health criteria **You may NOT be eligible if...** - Your lymphoma type or prior treatment history does not meet specific criteria - You have significant organ dysfunction or other conditions that make experimental therapy unsafe - Other exclusion criteria apply (your doctor will review in detail) Talk to your doctor to see if this trial is right for you.